SecBot SecBot
8-K ·Filed Jul 7, 2026

TOI

Oncology Institute, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001079973-26-000934
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▲ Bullish

The refinancing eliminates the overhang of the $86M convertible note (near-term maturity and dilution) and replaces it with a longer-dated term loan. The issued warrants (10M shares at $8.567, expiring Aug 2027) add potential future dilution but are OTM relative to current stock price and were issued to a creditor, not the public. Monitor TOI's ability to reach the $700M Net Revenue covenant by Q4 2027 and any future utilization of the permitted $25M ABL facility.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d
TOI ▼ -9.20% at T+20d
LONG call ✗ call lost -9.20% · α vs SPY -12.48% · entry $5.65 → $5.13
Next anchor: T+60d due 26d ago
Entry = T+0 close
Jul 7, 2026
via day close
T+1d
+3.54%
call +3.54% · α +2.69%
$5.85
settled 4mo ago
T+5d
+11.15%
call +11.15% · α +10.29%
$6.28
settled 3mo ago
T+20d
-9.20%
call -9.20% · α -12.48%
$5.13
settled 3mo ago
T+60d
Pending
due 26d ago

Price Chart

Loading chart...

Executive Summary

TOI refinanced its $86 million Deerfield convertible note by entering into a $75 million term loan with OrbiMed (maturity 2031, interest at SOFR+5.75% with 3% floor) and using ~$11M cash, eliminating near-term convertible debt overhang. As part of the Deerfield repayment, TOI issued 10,025,535 warrants with an $8.567 strike and August 2027 expiration for no additional consideration. The refinancing extends maturities, removes dilution risk from the convertible, and introduces a $700M minimum net revenue covenant starting Q4 2027.

Key Financial Metrics

Deal Value
$75.0M
Deal Type
credit_facility

Key Facts

  • TOI entered a $75 million senior secured term loan facility with OrbiMed, drawn in full on July 1, 2026.
  • Proceeds from the OrbiMed loan plus ~$11M cash on hand were used to repay the $86 million Deerfield senior secured convertible note due 2027.
  • The new loan bears interest at the higher of (i) 1-month CME Term SOFR and (ii) 3.00%, plus a 5.75% margin per annum.
  • The loan matures July 1, 2031; amortization begins 36 months after closing (quarterly payments of 7.5% of principal then outstanding).
  • A financial covenant requires minimum trailing-12-month Net Revenue of $700 million, commencing December 31, 2027.
  • As part of the note repayment, TOI issued 10,025,535 warrants to Deerfield at an exercise price of $8.567 per share, expiring August 9, 2027.
  • The facility is guaranteed by TOI's direct and indirect subsidiaries and secured by substantially all assets via a Pledge and Security Agreement.
  • The refinancing was completed without raising additional equity, per the company.

Financial Impact

Refinancing replaced $86M convertible debt (4% coupon, due 2027) with $75M term loan (SOFR+5.75%, 3% floor, due 2031), plus ~$11M cash outlay. The new loan carries higher cash interest but eliminates the conversion option, removes near-term maturity pressure, and provides a 5-year runway.

debtequity_dilutioninterest_expenseliquidity

Risk Factors

  • The $700M Net Revenue covenant (starting Dec 2027) creates a performance threshold that could constrain operations if revenue growth stalls.
  • The higher cash interest cost (SOFR+5.75% with 3% floor vs. 4% fixed convertible) will reduce net income and free cash flow.
  • Issuance of 10M warrants at $8.567 per share creates eventual dilution if exercised, though the strike is above the current price.
  • The loan is secured by substantially all assets, limiting future financing flexibility.
  • Covenants restrict dividends, M&A, additional debt, and transactions with affiliates.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Offices & Clinics of Doctors of Medicine
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001079973-26-000934
Exhibit: ex10x2.htm0001079973-26-000934
Exhibit: ex99x1.htm0001079973-26-000934
Document: toi_8k.htm0001079973-26-000934
Document: 0001079973-26-000934-index-headers.html0001079973-26-000934
Document: 0001079973-26-000934-index.html0001079973-26-000934
Document: 0001079973-26-000934.txt0001079973-26-000934
11 reports for TOI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for TOI — sortable, filterable
TypeNow
Aug 3, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$5.13awaiting T+20——
Jul 22, 2026
13w ago
Insider Buy
NEUTRAL ★ 2/10
$5.29awaiting T+20——
Jul 22, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$5.29awaiting T+20——
Jul 16, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$5.35awaiting T+20——
Jul 13, 2026
15w ago
Insider Buy
NEUTRAL ★ 3/10
$6.25awaiting T+20——
Jul 7, 2026
15w ago
8-K
BULLISH ★ 7/10
$5.65 $5.13▼ −9.20%▼ −12.48%—
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 3/10
$5.13 $5.85▲ +14.04%▲ +12.14%—
Jun 9, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$4.68 $5.85▲ +25.00%▲ +21.38%—
Apr 27, 2026
26w ago
Press Release
NEUTRAL ★ 1/10
$3.33 $4.59▲ +37.84%▲ +32.88%—
Apr 9, 2026
28w ago
Insider Cluster
MIXED ★ 5/10
$3.11 $3.80▲ +22.19%▲ +14.62%—
Showing 10 of 11

US Market Status

Market Open — Closes in 3h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026